ID
45646
Descripción
Principal Investigator: Neal Freedman, PhD, MPH, National Cancer Institute, Rockville, MD, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001286 The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of screening on cancer-related mortality and secondary endpoints in over 150,000 men and women aged 55 to 74. The screening component of the trial was completed in 2006. However, participants have been under follow-up for cancer incidence and mortality since that time. In addition, PLCO included a large biological sample biorepository which has served as a unique resource for cancer research, particularly for etiologic and early-marker studies. As part of these efforts, PLCO has been used for a large number of genome-wide association and exome sequencing studies for different types of cancer.
Link
Palabras clave
Versiones (1)
- 20/3/23 20/3/23 - Simon Heim
Titular de derechos de autor
Neal Freedman, PhD, MPH, National Cancer Institute, Rockville, MD, USA
Subido en
20 de marzo de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001286 The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)
Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sample ID sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Sample ID, histological type of sample, body site where sample was obtained, analyte type, tumor status of sample, and array platform of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
Similar models
Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sample ID sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Sample ID, histological type of sample, body site where sample was obtained, analyte type, tumor status of sample, and array platform of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
C2348585 (UMLS CUI [1,2])